Philippines Device Registration Roadmap and Timeline

1. Key takeaways

Philippine device registration runs in six stages: determine the class and the applicable pathway, confirm the holding entity and its LTO, prepare and authenticate the technical file, submit and pay, respond to technical review and deficiencies, and then hold and maintain the certificate. A Class A CMDN in practice takes about one to three months. A Class B, C or D CMDR has a statutory review period of 180 days from acceptance, and in practice usually takes six to nine months, extending to nine to twelve months where a deficiency round is required.

The gap between the statutory period and the practical period is not a criticism of the agency. It reflects the work that happens around the review: payment processing, scheduling, the exchange of clarification and the internal time a manufacturer needs to produce additional evidence. Planning on the statutory figure alone produces a schedule that assumes the applicant is as fast as the regulation permits.

• Six stages, from classification to post-market maintenance.
• Class A CMDN: about one to three months in practice.
• Class B, C and D CMDR: 180 days statutory from acceptance, six to nine months in practice, nine to twelve with a deficiency round.
• Abridged review target: 30 working days, where an ASEAN national regulator has already approved the product and AMDD-CSDT documents exist.
• Certificates run five years, with renewal filed within 90 days before expiry.

2. Legal basis

The authorisation framework comes from AO No. 2018-0002. The fast track comes from FC No. 2022-008, which sets a 30 working day target for products already cleared by an ASEAN national regulatory authority and documented to AMDD-CSDT structure. Processing time commitments rest on RA No. 11032, and the FDA Citizen Charter applies that law to specific transactions, including a 20 working day standard for a device manufacturer LTO.

3. Expert insights

Insight one: the real bottleneck usually sits before submission, not in review.

Laid out across the six stages, the LTO process at one to three months, the technical file preparation and the notarisation and Apostille work all happen before the file is submitted, and together they often account for more than a third of the total elapsed time. Many projects concentrate attention on how long the FDA will take, when the pre-submission stages are the part with the greatest controllability and the most room for improvement. Our recommendation is to plan backwards from the target launch month rather than forwards from the decision to enter.

Insight two: plan Class B, C and D at ten to fifteen months overall.

That range is the practical estimate once pre-submission work, review and a deficiency buffer are all included. Where the product already holds a CSDT-format approval in another ASEAN member state, the abridged route can compress the review segment to around 30 working days, and the overall timeline shortens materially. This is the practical foundation of the strategy of using one CSDT to reach several ASEAN markets, and it is worth testing early, because the availability of the abridged route depends on evidence that must exist before filing rather than being assembled afterwards.

Insight three: the deficiency letter is the main variable in the schedule.

During technical review the FDA issues a deficiency notice. The working figure in the industry is a 30 day window to submit the additional material. We emphasise that this window is a single opportunity rather than a buffer that can be drawn on repeatedly. Where the response is late or remains incomplete, the outcome can be a Letter of Disapproval (LOD), after which the application must be refiled, the fee paid again and the queue joined again from the start.

Insight four: the central discipline is getting the file right the first time.

In a market where review already takes a substantial period, the one lever that genuinely compresses the timeline is a submission free of deficiencies. That requires an independent internal quality check before filing: whether the ISO 13485 certificate scope covers the product being filed, whether the risk management report is complete, whether any labelling still carries Chinese text, whether the LOA has completed notarisation and Apostille, and whether product names and model designations match across every document in the set.

4. Practical recommendations

• Plan backwards and hold three months of buffer. Start from the target launch month, subtract six to nine months of review, subtract one to three months of LTO, subtract two months for documentation and authentication, then keep the remainder as buffer. The buffer is not padding; it is the allowance for the deficiency round that most files encounter.
• Move the Apostille step to the front. Where foreign public documents are involved, notarisation and Apostille take several weeks and some documents carry their own validity limits, so this is the task to start first rather than last.
• Establish an ASEAN reference approval early. An existing approval in Malaysia, Singapore or Thailand allows the CSDT file to be reused for the abridged route in the Philippines, which is the single largest available reduction in review time.
• Open the expiry register at the point of grant. Record the five-year expiry date and the 90 day renewal window immediately, and begin renewal preparation six months ahead so that the certificate never becomes the constraint on supply.

5. Verification checklist

• □ Confirm the class and pathway against the AMDD rules and the registerable device list.
• □ Confirm that the holding entity LTO is valid through the FDA Verification Portal.
• □ Confirm that LOA authentication is complete, with notarisation and Apostille verifiable online.
• □ Confirm that the ISO 13485 scope covers the product being filed.
• □ Confirm technical file completeness item by item against the internal QC checklist.
• □ Confirm the submission channel: eServices for Class A, the designated mailbox for Class B, C and D.
• □ Confirm that the expiry register records the five-year date and the 90 day window at the time of grant.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com